ICLR:NGS-ICON plc (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 212.27

Change

+0.09 (+0.04)%

Market Cap

USD 4.25B

Volume

1.45M

Analyst Target

USD 199.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Icon PLC is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+3.71 (+0.87%)

USD 34.17B
ILMN Illumina Inc

-1.45 (-0.98%)

USD 23.86B
NTRA Natera Inc

+25.85 (+19.13%)

USD 15.36B
EXAS EXACT Sciences Corporation

+0.57 (+1.14%)

USD 13.02B
MEDP Medpace Holdings Inc

+1.13 (+0.31%)

USD 9.93B
RDNT RadNet Inc

-1.03 (-1.23%)

USD 5.00B
SHC Sotera Health Co

-0.22 (-1.42%)

USD 4.49B
GH Guardant Health Inc

+1.88 (+6.32%)

USD 3.53B
NEOG Neogen Corporation

-0.16 (-1.04%)

USD 3.13B
TWST Twist Bioscience Corp

-2.77 (-6.12%)

USD 2.66B

ETFs Containing ICLR

IRESF iShares Public Limited Co.. 16.68 % 0.00 %

-0.10 (-0.80%)

N/A
EIRL iShares MSCI Ireland ETF 16.64 % 0.47 %

-1.39 (-0.80%)

USD 0.08B
PCIG Litman Gregory Funds Trus.. 10.24 % 0.00 %

-0.08 (-0.80%)

USD 0.03B
XGES:LSE Xtrackers MSCI Genomic He.. 4.62 % 0.00 %

+0.09 (+-0.80%)

N/A
BBH VanEck Biotech ETF 4.59 % 0.35 %

+0.36 (+-0.80%)

USD 0.43B
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.57 % 0.00 %

+0.16 (+-0.80%)

N/A
W311:XETRA HAN-GINS Indxx Healthcare.. 4.30 % 0.00 %

+0.01 (+-0.80%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 4.30 % 0.00 %

+0.02 (+-0.80%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 4.30 % 0.00 %

-0.01 (-0.80%)

N/A
QQQN VictoryShares Nasdaq Next.. 2.26 % 0.00 %

N/A

USD 0.02B
QQJE:CA Invesco ESG NASDAQ Next G.. 1.97 % 0.00 %

-0.13 (-0.80%)

CAD 0.99M
EQQJ:LSE Invesco NASDAQ Next Gener.. 1.83 % 0.00 %

+0.28 (+-0.80%)

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 1.78 % 0.00 %

N/A

N/A
JNDQ:AU BETAJNDQ ETF UNITS 1.77 % 0.00 %

-0.09 (-0.80%)

N/A
EQQJ:XETRA Invesco NASDAQ Next Gener.. 1.54 % 0.00 %

+0.25 (+-0.80%)

USD 0.05B
GNRX 0.00 % 0.55 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
IREMF 0.00 % 0.00 %

N/A

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

+0.04 (+-0.80%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.01% 40% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.01% 40% F 28% F
Trailing 12 Months  
Capital Gain -20.48% 40% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.48% 40% F 26% F
Trailing 5 Years  
Capital Gain 39.27% 75% C 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.27% 75% C 64% D
Average Annual (5 Year Horizon)  
Capital Gain 14.90% 62% D 68% D+
Dividend Return 14.90% 62% D 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.36% 92% A 64% D
Risk Adjusted Return 52.55% 92% A 80% B-
Market Capitalization 4.25B 95% A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.20 52% 39%
Price/Book Ratio 1.93 51% 49%
Price / Cash Flow Ratio 16.21 20% 19%
Price/Free Cash Flow Ratio 13.65 21% 27%
Management Effectiveness  
Return on Equity 7.99% 91% 72%
Return on Invested Capital 8.00% 94% 74%
Return on Assets 4.17% 91% 83%
Debt to Equity Ratio 39.67% 48% 47%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.